SIRPant Immunotherapeutics, Inc., a Biolocity portfolio company, has achieved a significant milestone in the field of immunotherapy. The company recently announced the FDA clearance of its Investigational New Drug (IND) application for SIRPant-M™, an autologous SIRPĪ±low activated macrophage immunotherapy. This exciting development marks a major step forward in the advancement of personalized and targeted treatments.
To learn more, visit the official announcement on SIRPant Immunotherapeutics’ website: https://sirpantimmunotx.com/news/sirpant-immunotherapeutics-announces-fda-clearance-of-ind-application-for-sirpant-m-autologous-sirp%ce%b1low-activated-macrophage-immunotherapy/.
Comments are closed.